TREAT Asia Calls for Expanded Access to Pediatric Dolutegravir

Facilitating access to formulations of the HIV medicine dolutegravir (DTG) that can be used by infants and children living with HIV in the Asia-Pacific is an urgent concern.

In light of recent U.S. and European regulatory approvals of a dispersible version of pediatric DTG, amfAR’s TREAT Asia program recommends steps that national HIV programs and advocacy groups can take in order to secure access to this medicine as quickly as possible.

Read the brief in full here.

Pediatric Dolutegravir: Securing Access to Dispersible Tablets for Children in the Asia-Pacific

Share This: